We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Sense Diagnostics team is skilled in the clinical care of severe brain injuries, with three practicing physicians among the founders.The SENSE scanner transmits low power radio waves through the patient’s brain every few minutes. It detects scattering by the blood cells and plasma when the signal encounters a hemorrhage. This fact allows our scanner to detect bleeding in minutes, not hours. The SENSE device was invented and designed by practicing clinicians and researchers. It will fit easily into the workflow and footprint of the ambulance and the ICU. It also doesn’t interfere with other treatments or monitors used the patient.
Current funding initiatives: FDA Approval (1Q18 -2Q20): $3.5-5 million. During this phase, the company will be conducting a pivotal clinical trials on Traumatic Brain Injury and Stroke patients. Targeting preparation and submission of required documentation to the FDA by June 2019. Initiating sales, production capabilities for product launch in mid 2020.